Synthesis and structure-activity relationships of ticlopidine derivatives and analogs as inhibitors of ectonucleotidase CD39
作者:Chunyang Bi、Laura Schäkel、Salahuddin Mirza、Katharina Sylvester、Julie Pelletier、Sang-Yong Lee、Thanigaimalai Pillaiyar、Jean Sévigny、Christa E. Müller
DOI:10.1016/j.bioorg.2023.106460
日期:2023.3
and cancer-promoting adenosine levels. In the present study, we performed an extensive structure–activity relationship (SAR) analysis of ticlopidine derivatives and analogs as CD39 inhibitors followed by an in-depth characterization of selected compounds. Altogether 74 compounds were synthesized, 41 of which are new, not previously described in literature. Benzotetrahydropyridines, in which the metabolically
噻氯匹定是噻吩并四氢吡啶家族的抗血栓形成前药。对于血小板抑制,它必须通过细胞色素 P450 酶进行氧化开环。生成的硫醇与嘌呤 P2Y 12的半胱氨酸残基反应血小板上的受体导致共价受体阻断。先前显示其完整、未代谢形式的噻氯匹定可抑制外核苷三磷酸二磷酸水解酶-1(NTPDase1,也称为分化簇 (CD) 39)。CD39 通过 ADP 催化 ATP 胞外水解为 AMP,AMP 进一步被 ecto-5'-核苷酸酶 (CD73) 水解为腺苷。CD39 抑制已被提议作为一种新策略来增加抗增殖 ATP 的细胞外浓度,同时降低免疫抑制和促癌腺苷水平。在本研究中,我们对作为 CD39 抑制剂的噻氯匹定衍生物和类似物进行了广泛的构效关系 (SAR) 分析,随后对所选化合物进行了深入表征。总共合成了 74 种化合物,其中 41 个是新的,以前没有在文献中描述过。苯并四氢吡啶,其中代谢不稳定的噻吩被苯环取代,被发现是一类新的变构